We are live on
!
Find out more
CI
Clal Insurance Portfolio holdings
AUM
$16.6B
1-Year Est. Return
68.34%
This Fund
S&P 500
This Quarter
Est. Return
+1.91%
1 Year Est. Return
+68.34%
3 Year Est. Return
+151.82%
5 Year Est. Return
+175.48%
10 Year Est. Return
+729.64%
AUM
$3.76B
AUM Growth
-$34.7M
(-0.91%)
Cap. Flow
-$64.8M
Cap. Flow
% of AUM
-1.72%
Top 10 Holdings %
Top 10 Hldgs %
65.5%
Holding
82
New
17
Increased
17
Reduced
20
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$68.1M |
| 3 |
Perrigo
PRGO
|
+$46M |
| 4 |
MLNX
Mellanox Technologies, Ltd.
MLNX
|
+$42.5M |
| 5 |
The Mosaic Company
MOS
|
+$36.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Biotechnology ETF
IBB
|
+$130M |
| 2 |
iShares US Pharmaceuticals ETF
IHE
|
+$116M |
| 3 |
Viatris
VTRS
|
+$60.9M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$40.7M |
| 5 |
XYZ
Block Inc
XYZ
|
+$37.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.53% |
| 2 | Financials | 6.72% |
| 3 | Industrials | 5.99% |
| 4 | Healthcare | 5.31% |
| 5 | Communication Services | 5.07% |
Similar funds
AIMCA
EIP
IG
BCIM
UCFA
VMPIC
LCOV
Clal Insurance's Q1 2018 Portfolio in Review
As of Q1 2018, Clal Insurance held 82 positions worth $3.76B, down 0.91% from $3.8B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Clal Insurance's Q1 2018 filing shows 17 new, 17 increased, 20 reduced and 9 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 1,352,197 shares worth $119M. The largest sale was iShares Biotechnology ETF, an estimated $130M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 13% a quarter earlier, followed by Financials and Industrials.
- Clal Insurance's largest Q1 2018 buy was State Street SPDR S&P Biotech ETF: 1,352,197 shares worth $119M.
- Clal Insurance added most to Vanguard S&P 500 ETF in Q1 2018, an estimated $68.1M increase.
- Clal Insurance's biggest Q1 2018 reduction was iShares Biotechnology ETF, cutting an estimated $130M.
- Clal Insurance fully exited iShares US Pharmaceuticals ETF in Q1 2018, selling an estimated $116M.
- Clal Insurance's ten largest holdings make up 66% of its $3.76B portfolio in Q1 2018.
- Clal Insurance opened 17 new positions and closed 9 in Q1 2018.
- Clal Insurance's portfolio value fell 0.91% quarter-over-quarter to $3.76B.
Based on Clal Insurance's 13F filing for Q1 2018, filed 2 May 2018.